Category: Intellectual Proprety

Access to medicines amendment of the WTO TRIPS Agreement– hype or hope?

By: Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, e.f.m.t.hoen@umcg.nl On 30 January the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome entry into force of...

/ 5 April 2017

Amendment of the TRIPS Agreement

WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally built into the TRIPS Agreement after...

/ 23 January 2017

Civil Society Calls on WHO to Include Report from UN’s High Level Panel on Medicines on WHO Board Agenda

Dear Director General Dr. Margaret Chan Request to include discussion of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines at the next WHO Board meeting As members of the Make Medicines Affordable campaign, and other Civil...

/ 28 February 2016

Morocco: Creation of a collective for t the right to health in the framework of the negotiations of the EU ALECA

At a time when the Kingdom of Morocco and the European Union are preparing to resume negotiations on the "comprehensive and thorough free trade agreement" (FTAA), Moroccan civil society unites to bell Alarm about ALECA's danger of access to generics...

/ 12 January 2016

African Treatment Advocates Call on ViiV Healthcare to Unlock Access to Dolutegravir for North Africa Now

Harare, December 1st, 2015 Today, at the International Conference on AIDS and STIs in Africa (ICASA), treatment advocates and activists from all over Africa united to urge ViiV Healthcare to allow affordable access to an essential drug in four North...

/ 2 January 2016

Building Capacity on Intellectual Property, Free Trade Agreement and Access to Medicines Workshop

ATL MST – ITPC MENA WORKSHOP TUNISIA 16, 17 & 18 NOVEMBER 2015 One of the most pressing issues in the 21st century is the lack of availability of essential medicines to poor patients in underdeveloped and developing countries. The...

/ 20 November 2015

HIV

HIV : The MENA region still has one of the lowest HIV prevalence rates in the world (0.1%). However, MENA is increasingly becoming a region of concern regarding HIV and AIDS. Since 2001, new HIV infections have risen by 35%....

/ 23 October 2015

Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatment in Morocco

According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management of HCV infection has been hampered...

/ 26 June 2015

Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Suffering from HCV Infection

The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis C Virus (HCV), sofosbuvir, available to...

/ 20 May 2015

The first Middle East and North Africa Community Advisory Board (MENA-CAB)

Casablanca, Morocco, 28 June-01 July 2014 Despite the fact that HIV prevalence in the countries of the Middle East and North Africa is believed to be low at least among the General Population, the rate of increase of new cases...

/ 10 July 2014